Protagonist Therapeutics (NASDAQ: PTGX) announced that Takeda received U.S. Food and Drug Administration approval for MIMRYLO (rusfertide), a subcutaneously administered ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE